Market Expansion Strategic partnerships with international distributors and medical device integrators have already occurred (Australia via AKVA Surgical; OrthoPediatrics in the US), suggesting opportunities to scale CERAMENT in additional high-potential regions and hospital networks through targeted distribution agreements.

Orthobiologics Demand Strong focus on radiopaque injectable osteoconductive and drug-eluting bioceramics positions BONESUPPORT to address bone defects, fractures, and osteomyelitis, indicating cross-selling potential across trauma centers, orthopedic departments, and infection control programs.

Regulatory Readiness Recent FDA market authorization for Cerament G and existing global distribution show a capability to navigate regulatory pathways, enabling expedited entry for new CERAMENT variants or adjunctive products in markets with orthopedic and infectious disease needs.

Clinical Adoption Product lineup targets bone healing timelines of six to twelve months, aligning with hospital performance metrics on patient throughput and reduced revision surgeries, offering value-based selling angles focused on outcomes and cost savings.

Engaged Leadership Active investor and market communications (Capital Markets Day, AGM) alongside ongoing partnerships signal visibility and credibility, providing sales teams with talking points to engage C-level stakeholders and procurement about long-term strategic sourcing.